Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real‐world clinical setting. (30th July 2019)

• Record Type: Journal Article
• Authors: Fougerousse, A.‐C.; Maccari, F.; Beauchet, A.; Parier, J.; Boulard, C.; Becherel, P.‐A.; Quiles‐Tsimaratos, N.; Le Guyadec, T.; Thomas‐Beaulieu, D.; Halioua, B.; Begon, E.; Bastien, M.; Perrot, J.‐L.; Pallure, V.; Bilan, P.; Steff, M.; Pfister, P.; Vermersch‐Langlin, A.; Boyé, T.; Mery‐Bossard, L.; Maillard, H.; Kemula, M.; Girard, C.; Poiraud, C.; Monfort, J.‐B.; Kupfer‐Bessaguet, I.; Perrussel, M.; Lons‐Danic, D.; Sultan, N.; Lorier, E.; Zeitoun, M.; Wagner, L.; Gabison, G.; Mahé, E.;
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 33:Number 12(2019)
• Page Start: e476
• Page End: e478
• Publication Date: 2019-07-30
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.15804
• Languages: English
• ISSNs: 0926-9959